
3rd International Electronic Conference on Medicinal Chemistry
Part of the International Electronic Conference on Medicinal Chemistry series
1–30 Nov 2017
- Go to the Sessions
- Event Details
Welcome from the Chair
Further to the success of the two first editions, Pharmaceuticals, a peer-reviewed journal edited by MDPI, is proud to organize and sponsor the 3rd International Electronic Conference on Medicinal Chemistry. Contributions dealing with any discipline promoting research in drug discovery and development will be welcome.
The conference will be held online (www.sciforum.net/conference/ecmc-3) from November 1–30, 2017. It will enable you to share your recent results with scientists of academic and industrial groups from all over the world.
Participation, as an author or a visitor, is ABSOLUTELY FREE (simply create an account on the home page). Abstracts of the presentations will be published, upon authorization of the authors, in a meeting report after the conference.
On behalf of our dynamic editorial staff and active scientific committee, we warmly invite you to join us during this third edition and we look forward to posting your contributions.
All participants of ECMC-3 are welcome to submit the extended work to the Pharmaceuticals Special Issue "Selected Papers from the 3rd International Electronic Conference on Medicinal Chemistry".
Conference Chair
Dr. Jean Jacques Vanden Eynde |
![]() |
Conference Committee
IPBLN-CSIC, Spain |
Universidade do Porto, Portugal |
University of Nebraska Medical Center, USA |
Haute Ecole Provinciale de Hainaut-Condorcet, Belgium |
Université Libre de Bruxelles, Belgium |
Universidade Federal do Rio de Janeiro, Brazil |
Università degli Studi di Cagliari, Italy |
Call for Papers
The conference will cover a wide range of aspects involved in drug discovery and development. A non exhaustive list of topics that will be considered comprises:
- ADMET
- Animal experimentation
- Assay development
- Biomarkers
- Biomolecules
- Biosensors
- Biotechnology
- Chemical synthesis
- Clinical studies and side effects reports
- Combinatorial chemistry
- Drug delivery (including bioconjugates and prodrugs)
- High throughput screening
- Hit identification
- Imaging techniques
- In silico experiments
- In vitro studies
- Lead optimization
- Omics
- Pharmaceutical analysis
- Scale-up
- Structure–activity relationships
- Target selection
After the conference, proceedings will be published free of charge thanks to the sponsoring of the journal Pharmaceuticals, in a meeting report. Authors of the most outstanding contributions, as selected by the Scientific Committee, will be invited to publish their work as a research article free of charge or at a discounted price, in a Special Issue of the journal Pharmaceuticals.
The Scientific Committee looks forward to receiving contributions in response to this call and will be glad to provide any further information to interested parties. Questions may be addressed to the chairman via e-mail at [email protected] or to the Pharmaceuticals editorial office at [email protected].
We thank you in advance for your attendance of this conference and look forward to a stimulating exchange.
Conference Chairs

Formerly head of the Department of Organic Chemistry (FS), University of Mons-UMONS, 7000 Mons, Belgium
[email protected]
Conference Committee

Department of Molecular Biology, Instituto de Parasitología y Biomedicina López-Neyra, (IPBLN-CSIC), PTS Granada, Av del Conocimiento 17, 18016 Granada, Spain
structure-function of RNA; aptamers; antisense; ribozymes; viral RNA genomes; RNA as tool; therapeutic RNAs
[email protected]

Laboratório de Química Orgânica e Farmacêutica, Departamento de Ciências, Químicas, Faculdade de Farmácia, Universidade do Porto, Rua Jorge Viterbo Ferreira 228, 4050-313, Porto, Portugal
medicinal chemistry; organic synthesis; heterocycles, P-glycoprotein; anticancer; anticoagulants; chiral drugs; marine natural products
[email protected]

Department of Pathology & Microbiology University of Nebraska Medical Center, USA
host defense antimicrobial peptides, structural bioinformatics, biomolecular NMR
[email protected]

Formerly professor at the Haute Ecole Provinciale de Hainaut-Condorcet, 7330 Saint-Ghislain, Belgium
medicinal chemistry, organic synthesis, parasitic diseases, orphan drugs
[email protected]

Faculté de Pharmacie, Université Libre de Bruxelles, Campus Plaine CP 205/5, 1050 Brussels, Belgium
medicinal chemistry; anticancer metal complexes; asymmetric synthesis
[email protected]

Universidade Federal do Rio de Janeiro, IPPN, CCS, Bloco H - Ilha do Fundão, Rio de Janeiro, RJ - 21941-902, Brazil
molecular modeling; computer-aided drug design; bioinformatics; chemoinformatics
[email protected]

Università degli Studi di Cagliari, Dipartimento di Scienze Chimiche e Geologiche, Cittadella Universitaria, SS 554, bivio per Sestu, 09042, Monserrato (CA), Italy
peptide synthesis; peptide nucleic acid; indole synthesis; amide synthesis; mechanochemical reaction; borrowing hydrogen; microwave; heterocycle synthesis; hydroxamic acids
[email protected]
Instructions for Authors
Submissions should be done by the authors online by registering with www.sciforum.net, and using the "Start New Submission" function once logged into system.
Researchers interested in attending the conference must submit, on this website and not later than 15 October 2017, an abstract of the work they intend to present.
After the abstract is accepted by the Scientific Committee (1-5 days after receipt of the abstract), the authors will be invited to prepare a full description of their work preferably under the form of a PowerPoint presentation, and to upload it before 20 October 2017 to ensure final check.
The presentations will be accessible on https://sciforum.net/conference/ecmc-3 during the time of the conference.
Authors are encouraged to prepare a presentation using the template provided by the conference. Slides will be displayed directly in the website using Sciforum.net's proprietary slides viewer. They can be prepared in exactly the same way as for any traditional conference where research results can be presented. Slides should be converted to the PDF format before submission so that our process can easily and automatically convert them for online displaying.
Electronic Conference on Medicinal Chemistry PPT template file
Electronic Conference on Medicinal Chemistry Poster template file
The following organization is recommended for your presentation:
- Length of the presentation: no more than 30 slides
- Slide 1 (strictly one slide): Title, Authors’ names, Affiliation(s), email address of the corresponding Author, and, not mandatory, logos of the laboratory and/or institution;
- Slide 2 (strictly one slide): Graphical Abstract, repeat the title of the presentation but avoid other text as far as possible;
- Slide 3 (strictly one slide): Abstract (max 200 words) and 3-5 keywords separated by semicolons;
- Slide 4 and following slides: should contain (in the given sequence) Introduction, Results and Discussion; Conclusions.
- Last slide: Acknowledgments and, not mandatory, logos of sponsors of the work.
MDPI AG, the publisher of the Sciforum.net platform, is an open access publisher. We believe that authors should retain the copyright to their research works. Hence, by submitting a contribution to this conference, the authors retain the copyright of their contribution, but they grant MDPI AG the non-exclusive right to publish this contribution online on the Sciforum.net platform. This means the authors can easily submit their contribution to any scientific journal at a later stage and transfer the copyright to its publisher (if required by that publisher).
List of accepted submissions (76)
Id | Title | Authors | Presentation | ||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
sciforum-013793 | Interrelation between Histamine and Serotonin, Dopamine, GABA, IGF-1 in a Growth Hormone (GH) Deficient Group under rh-GH Replacement Therapy | , , , |
![]() |
Show Abstract |
|||||||||||||||||||||||||||||||||||||
Aim: To evaluate relationship between histamine (HIST), serotonin (5-HT), dopamine (DA), gamma-amino-butyric acid (GABA) and IGF-1 in 20 GH-deficient boys. Research design and methods: This study included 20 boys (5-14 years) with GH deficit clinically established and a 10 matched normal group with no endocrine dysfunction. All of GH deficient patients underwent GH replacement therapy. In 2017, all subjects were tested by analytical methods for blood: HIST,GABA,DA,5-HT,IGF-1. Results: We divided this study group into a low HIST lot 1 (10 subjects): HIST median: 3.48 nM/L and a high HIST lot 2 (10 subjects): HIST median: 11nM/L. Median parameters in lot 1 vs. lot 2 were: 5-HT: 212.5 vs. 370ng/mL, DA: 30 vs. 45pg/ml, GABA: 30 vs. 56.5ng/mL, IGF-1: 373.5 vs. 200ng/mL. Median values in normal subjects were as it follows: HIST: 5.55nM/L; 5-HT: 235.5ng/mL; DA: 31.5pg/mL; GABA: 81ng /mL. T-Test revealed a statistical significance between HIST in lot 1 vs. lot 2 (P<0.001), HIST in lot 1 vs. normal group (P<0.01) or HIST in lot 2 vs. normal group (P<0.01).We can also underline a statistical significance between 5-HT in lot 1 vs. lot 2 (P<0.05) or in lot 2 vs. normal group (P=0.01). Conclusion: Our study underlined a HIST/5-HT positive relationship in low HIST group vs. a negative relationship HIST/5-HT in high HIST group, with small IGF-1 increments under r-GH therapy. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-014505 | Old Pharmaceuticals with New Applications: the Case Studies of Lucanthone and Mitoxantrone | , , , , , , |
![]() |
Show Abstract |
|||||||||||||||||||||||||||||||||||||
The decline or leveling of the output of the R&D programs of the pharmaceutical companies may suffered recent changes when compared to earlier years of the 21st century. Although a major responsible for this increase is the immunopharmacology-based treatments, small molecules still play an important role. 1 Medicinal chemistry approaches to find a small molecule lead compound, which shows the desired pharmacological activity, continue to use as sources natural products, synthesis, and existing drugs. In this communication, we will give examples of antitumor small molecules lead compounds obtained in our research group that arise from two existing drugs, lucanthone and mitoxantrone (MTX). One aim in medicinal chemistry is the study of drug metabolites, and very recently we engaged a project that intend to understand the influence of metabolites in the cardiotoxicity of an antitumor drug, MTX, approved in 1987 as an antitumor drug and in 2002 for use in multiple sclerosis. Although the main human MTX metabolites have been identified, their putative cardiotoxicity was not yet assessed. Herein, we also exemplify MTX drug metabolites as potential sources of new drugs. Initially, the MTX-naphthoquinoxaline metabolite (NAPHT) was synthetized and studies on NAPHT cardiotoxicity revealed that the parent drug, MTX, caused a higher disruption in the energetic pathways in a cardiac model in vitro, whereas autophagy is involved in the toxicity of both compounds; 2 therefore, this metabolite should be regarded as a good option for a safer anticancer therapy since it is less cardiotoxic than MTX. Moreover, previous data has shown that NAPHT can have a potential role on MTX’s anticancer effects. The case studies presented herein are expected to contribute to a recent trend in drug discovery, with the involvement of old pharmaceuticals. To us, existing drugs will continue to provide a fruitful solution in drug discovery and development.
Acknowledgements: We thank FCT/MCTES and ERDF through the COMPETE–POFC programme, under the Strategic Funding UID/Multi/04423/2013, the project PTDC/MAR-BIO/4694/2014 (POCI-01-0145-FEDER-016790; 3599-PPCDT) and PTDC/DTP-FTO/1489/2014 (POCI-01-0145-FEDER-016790) in the framework of PT2020, to INNOVMAR (NORTE-01-0145-FEDER-000035, NOVELMAR), supported by NORTE 2020, under PORTUGAL 2020, through ERDF.
References:
|
|||||||||||||||||||||||||||||||||||||||||
sciforum-014443 | New Hit Compounds Targeting Odorant Binding Proteins (OBPs) as Putative Repellents | , , |
![]() |
Show Abstract |
|||||||||||||||||||||||||||||||||||||
Mosquitoes are responsible for the transmission of serious and potentially fatal diseases to humans, such as malaria, dengue fever, West Nile fever, leishmaniasis and more recently Zika virus[1] infection. According to the World Health Organization, the prevalence of human mortality causing from infected mosquitoes amounts to one million, annually.[2,3] Nowadays, the increasing resistance of vectors to existing repellents render them as ineffective, creating the need for development of novel repellents with advanced properties to the existing ones in terms of duration of the protection, minimum effective dose, efficacy against a wide variety of insects’ bites and safety. The main goal of the current study is the discovery of novel hit compounds which may evolve as insect repellents by performing a combination of computational and analytical chemistry methodologies. Particularly, a pharmacophore-based virtual screening of natural compound libraries coupled with molecular docking were applied to identify novel hits towards Odorant Binding Protein 1 (OBP1) a molecular target for the most widely used synthetic repellents DEET[4,5] and Icaridin[6]. Compounds were selected to bear the appropriate physicochemical properties associated with insect repellency. Six compounds were evaluated against female mosquitoes (Aedes albopictus). Results presented insect repellent activity of 35-57,9% compared to untreated hand which indicate the proposed scaffolds as starting points for further structure optimization. References [1] G. S. Rawal et al., J Family Med Prim Care 2016, 5, 523-527. [2] R. Lozano et al., Lancet 2012, 380, 2095-2128. [3] World Health Organization. Vector-borne diseases fact sheet N. 387. WHO website http://www.who.int/mediacentre/factsheets/fs387/en/ WHO, 2016 [4] K. E. Tsitsanou et al., Cell Mol Life Sci 2012, 69, 283-297. [5] S. E. Zografos et al., ''QSAR in Environmental and Health Sciences", 65-99. [6] C. E. Drakou et al., Cell Mol Life Sci 2017, 74, 319-338. Acknowledgements This study was supported by “IKY FELLOWSHIPS OF EXELLENCE FOR POSTGRADUATE STUDIES IN GREECE-SIEMENS PROGRAM”. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-014920 | Analysis of the Binding Site of αS1-Casein to its Cellular Receptor TLR4 by Selective Inhibitors and Microscale Thermophoresis | , , , , , , |
![]() |
Show Abstract |
|||||||||||||||||||||||||||||||||||||
The human milk protein αS1-casein was recently reported to induce secretion of proinflammatory cytokines via Toll-like receptor 4 (TLR4)1. In this study, the binding site of αS1-casein to TLR4 was identified by selective inhibition of the intracellular binding domain and extracellular ecto-domain of TLR4. For this, Interleukin 8 (IL-8) secretion was monitored after stimulation of TLR4/MD2 (myeloid differentiation factor 2)/CD14 (cluster of differentiation 14)-transfected HEK293 cells (TLR4+) and Mono Mac 6 cells (MM6) with recombinant αS1-casein, or lipopolysaccharide (LPS) as control. The αS1-casein-induced IL-8 secretion was inhibited by TAK-242, an antagonist of the intracellular binding site and mianserine, an antagonist of the extracellular binding domain. TAK-242 inhibited αS1-casein-induced IL-8 secretion with an IC50 of 259 nM and LPS-induced IL-8 secretion with an IC50 of 23 nM. Mianserine was found as moderate inhibitor of the αS1-casein-induced IL-8 secretion with an IC50-range between 10-51 µM. Therefore, we suggested αS1-casein as an inhibitor of the extracellular binding site of TLR4. These findings were supported by binding experiments using microscale thermophoresis (MST). Human αS1-casein bound to the purified extracellular TLR4/MD2-complex with a KD of 2.2 µM in comparison to LPS binding TLR/MD2 with a KD of 8.7 µM. Furthermore αS1-casein showed binding to MD2 with a KD of 0.3 µM and CD14 with a KD of 2.7 µM. In addition, human αS1-casein induced IL-8 secretion via TLR4 was inhibited by inhibitory anti-CD14-IgA. Human αS1-casein induced proinflammatory effects by binding to the ecto-domain of TLR4 and CD14 is required as cofactor. Hence human αS1-casein activates TLR4 in a different manner than LPS. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-014504 | Study of Antiviral Compounds in the Conditions of Mixed Infections | , , , , |
![]() |
Show Abstract |
|||||||||||||||||||||||||||||||||||||
Mixed viral infection is one of the current and unexplored issues of human infectious diseases. A special place in the development of these pathologies is occupied by adeno- and herpes viruses that are able to persist for a long time in a latent condition in the body. There is a huge lack of knowledge about antiviral activities of specific drugs during the mixed infections. The study of know drugs and discovery of new compounds using not only standard mono-infections but also with created mixed infections is a topical and a new direction in antivirus screening. Previously in our department, the models of adeno-herpetic infections in cells of different origins were created and the features of the development of viral infections in these systems were studied. The model of simultaneous adeno-herpetic infection of MDBK cells was used for the analysis of the antiherpetic drug acyclovir (ACV) and for research of new fluorine-containing derivatives of L-phenylalanine (10S-23 and 10S-24, synthesized in Institute of Organic Chemistry of the NAS of Ukraine). Determination of the antiviral activity accessed via real-time PCR and infectious virus yield reduction assay demonstrated the inhibitory effect of these compounds on the late stage of the HSV-1 and HAdV5 reproduction. With the presence of 10S-24 and ACV in the conditions of mono-infection, HSV-1 DNA replication was inhibited on 39 and 100%, respectively. Furthermore, the significant delays of HSV-1 reproductions were observed, the titer of virus obtained de novo reduces on >99%. It was shown that for adenovirus infection of the cells, all compounds reduced the titer of the virus on 34-96%. Use of the ACV under mixed infection led to the 46% loss of the drug activity against HSV-1. The application of 10S-23 and 10S-24 at mixed infection induced a decrease of effectiveness of the compounds relatively herpes simplex virus by 58-73% and 16-57%, respectively. It was shown that compounds have been not effective against HAdV5 under conditions of co-infection of cells. An abnormal action of drugs in co-infected cells indicates the need for further study of the mechanisms and targets of antiviral activity of compounds in such conditions, because using these compounds can be ineffective in medical practice. Acknowledgements This work was supported by a President’s of Ukraine grant for competitive projects F70 of the State Fund for Fundamental Research. |
Copyright
MDPI AG, the publisher of the Sciforum.net platform, is an open access publisher. We believe that authors should retain the copyright to their research works. Hence, by submitting a contribution to this conference, the authors retain the copyright of their contribution, but they grant MDPI AG the non-exclusive right to publish this contribution online on the Sciforum.net platform. This means the authors can easily submit their contribution to any scientific journal at a later stage and transfer the copyright to its publisher (if required by that publisher).
Best Presentation Award
This year, as a sponsor, Pharmaceuticals would like to award the best presentation as elected by all the organizers. The Award will consist of 500 Swiss Francs. We look forward to posting your contributions.
Criteria for Evaluation of Best Presentation Award 2017:
Criteria
- Full PPT presentation must be submitted to ECMC-3.
- The quality of the presentation.
- The scientific content of the presentation
Evaluation
- Each Evaluation Committee member will give an assessment for each applicant in terms of the criteria outlined above.
- Total score for each presentation will be ranked, from highest to lowest.
- If two or more students get the same score, further evaluation will be carried out.
- All decisions made by the Evaluation Committee are final.
Best Presentation at ECMC-3
Pharmaceuticals and the Organizing Committee of ECMC-3 congratulate Jalal Soubhye who received an award for the best presentation at ECMC-3:
Topic: Dual Anti-Inflammatory and Anti-Bacterial Effects of Phenylhydrazide and Phenylhydrazone Derivatives
authored by Jalal Soubhye,
Laboratoire de Chimie Pharmaceutique Organique, Faculté de Pharmacie, Université Libre de Bruxelles, Campusplaine, CP 205/5, 1050 Brussels, Belgium.
"Currently, Dr. Jalal Soubhye works as academic researcher at the Université Libre de Bruxelles (ULB) in the field of medicinal chemistry, whose research focuses on pharmacological design, synthesis and evaluation of new chemical substances with therapeutic potential. His current research interests are in the development and evaluation (in vitro and in vivo) of myeloperoxidase inhibitors as anti-inflammatory agents. Understanding of the mechanism of inhibition is very important to obtain new potent and safe inhibitors. In addition, he is working on design, synthesis and evaluation of new antimicrobial agents."
Exhibition Hall
Electronic Exhibition Hall of ECMC - Develop and Strengthen Your Brand
- Free of charge for companies exhibited in 2017.
- High visibility: The last edition of this series provided the opportunity to more than 10,000 visitors to browse
among 42 relevant slide shows and videos, presented by 150 authors from 22 countries. - Super easy to prepare: a short introduction of your company, and a PPT presentation (less than 10 slides) to show super star products.
Euriso-top Founded in January 1991 by a group of researchers from the Commissariat à l'Energie Atomique (CEA), Euriso-Top became a leading producer of deuterated solvents and stable isotope labelled compounds in Europe, thanks to an incomparable knowledge.
Read more...With a large catalog of thousands of chemical compounds covering various fields of application (Proteomics and Genomic research, Biotechnology discovery, Organic synthesis, Pharmaceutical development, Manufacturing industry), Euriso-top, has been supplying for 25 years the scientific community with stable isotope labeled chemicals, isotopic gases, NMR solvents, isotopic metals, Clinical trials substrates.
ELVESYS is an innovative self-funded company that started the commercialization of microfluidic instrumentation in 2011. ELVESYS aims to become a key research partner in the microfluidic field because we believe this domain will be the heart of next technological revolution.
Read more...Doubling its turnover every 9 months, in just 4 years its ELVEFLOW brand has become the world leader of high performance microfluidic flow control. Rewarded by more than 10 entrepreneurial distinctions, ELVESYS launched two sisters companies in 2013 and 2014, respectively specialized in the biological environment control, the microfluidic device design and fast microchip prototyping.
Hielscher Ultrasonics GmbH: High-power ultrasonic processors for liquid processing
Hielscher Ultrasonics specializes in the design, development and production of ultrasonic devices - both for use in laboratories as well as for industrial applications. Due to the outstanding power of the ultrasonic processors and the high quality standards, Hielscher became the world's leading supplier of high performance ultrasonic equipment. The product range of Hielscher Ultrasonics includes ultrasonic devices to / for
Read more...- Dispersing
- Synthesis of nanoparticles
- Desaggregieren / Disagglomerating
- Particle Size Reduction (Wet-milling / fine-grinding of micro-and nano-scale particles)
- Homogenization
- Emulsification
- Extraction
- acceleration of chemical reactions (Sonochemistry)
- Wire cleaning
A leading Belgian company distributing laboratory instruments and furniture.
As a distributor of laboratory instruments and lab furniture, Analis is primarily oriented towards research activities, biotechnology applications, chemistry, clinical chemistry and medical in vitro diagnostics and quality control.
Read more...We are actively involved in the biotechnological and pharmaceutical sector (from basic research to production), as well as in the agro and food industry. Our mission is to provide researchers in proteomics, genetics and cellular analysis with appropriate professional instruments and support tools.
Established in Namur in 1927, Analis employs more than 130 people in two locations: The head office is in Suarlée (NAMUR) in the south of Belgium and we have a branch office in Sint-Denijs-Westrem (GENT) in the north.
Thanks to acquisitions, distribution activities and constant innovation, our company has grown and integrated new technologies. Analis covers all aspects of laboratory management: from laboratory project design to complete maintenance of customer’s installed equipment. We structured our organization in order to guide each (research) laboratory with the necessary expertise, application support, technologies and solutions in the following fields: Life Sciences;- In Vitro Diagnostics; Laboratory Equipment; Analytical Chemistry; Materials Testing; Metrology; Laboratory Furniture by ARDESTA.
Our priority is to offer a high level of application and service support. Furthermore, by offering a full range of flexible automation systems, we help each laboratory to increase its lab productivity.
Analis is certified ISO9001-2008, including conception, production, distribution and technical assistance.
Analis also runs a research laboratory, ‘Analis R&D Diag’, that develops electrophoresis and CE in vitro diagnostic kits (CEOfix™). ANALIS R&D Diag is focused on analytical method development through the use of capillary
MDPI (Multidisciplinary Digital Publishing Institute) is an academic open-access publisher with headquarters in Basel, Switzerland. Additional offices are located in Beijing and Wuhan (China), Barcelona (Spain) as well as in Belgrade (Serbia).
Read more...MDPI publishes 179 diverse peer-reviewed, scientific, open access, electronic journals, including Molecules (launched in 1996; Impact Factor 2.861), the International Journal of Molecular Sciences (launched in 2000; Impact Factor 3.226), Sensors (launched in 2001; Impact Factor 2.677), Marine Drugs (launched in 2003; Impact Factor 3.503), Energies (launched in 2008; Impact Factor 2.262), the International Journal of Environmental Research and Public Health (launched in 2004; Impact Factor 2.101), Viruses (launched in 2009; Impact Factor 3.465), Remote Sensing (launched in 2009; Impact Factor 3.244), Toxins (launched in 2009; Impact Factor 3.030), Nutrients (launched in 2009; Impact Factor 3.550), and Pharmaceuticals (CiteScore 4.9). Our publishing activities are supported by more than 15,700 active scientists and academic editors on our journals' international editorial boards, including several Nobelists. More than 263,500 individual authors have already published with MDPI. MDPI.com receives more than 8.4 million monthly webpage views.
Tropical Medicine and Infectious Disease (ISSN 2414-6366) is an international, scientific, open access journal of tropical medicine and infectious disease published quarterly online by MDPI. It is the official journal of The Australasian College of Tropical Medicine.
All the latest news, products, jobs, events and much more pertaining to chemistry, life science and analytics can be found on the CHEMIE.DE online portals. bionity.com is our life science flagship. It addresses readers who are interested in facts and trends from life science, biotechnology and pharma—and all this in four different languages! A total of around 700,000 page views per month confirm there is great interest in bionity.com and its information services.
Pharmaceuticals (ISSN 1424-8247; CODEN: PHARH2) is an open access journal of medicinal chemistry and related drug sciences, published quarterly online by MDPI. Citations are available in PubMed, full-text archived in PubMed Central. Following Scopus, the 3-year *CiteScore* of Pharmaceuticals is 4.9 in 2016. Pharmaceuticals is now ranked #8/168 in the category "Pharmaceuticals Science".
LATOXAN is the leading producer of venoms from snakes, scorpions and batrachians with over 300 different venoms worldwide available. LATOXAN also produces and supplies venom toxins, plant, plant small molecules and screening libraries. LATOXAN supplies Pharmaceutical Industry, Academic and Pharma Research centres and worldwide distributors of Life Science Reagents.
Conference Organizers
Dr. Franck Vazquez, MDPI AG, Basel, Switzerland
Ms Changzhen Fu, MDPI AG Branch Office, Wuhan, China
Ms Flora Li, MDPI AG Branch Office, Wuhan, China
List of Keynotes & Videos
Old pharmaceuticals with new applications: the case studies of lucanthone and mitoxantrone
Related papers Old Pharmaceuticals with New Applications: the Case Studies of Lucanthone and Mitoxantrone
Synthesis,Characterization,Molecular docking and Structure-Activity Relationships of Novel Thiazolo[3,2-α]pyrimidines as Prospective Acetylcholinesterase Inhibitors
Related papers Synthesis, Characterization, Molecular docking and Structure-Activity Relationships of Novel 2-Arylidene- and 2-Aminomethylenethiazolo[3,2-a]pyrimidines as Prospective Acetylcholinesterase Inhibitors
Electrochemical Detection of Salmonella via On-surface Isothermal Amplification of its Genetic Materia onto Highly Stable and Reproducible Indium Tin Oxide Platforms
Searching for bioactive molecules in prostate cancer from Mayan traditional medicinal plants
C. Round Table on Nanomedicines
This round table is organized with the help of our media partner Precision Nanosystems.
Precision NanoSystems (PNI) creates innovative solutions for the discovery, development and manufacture of novel nanoparticles for use as medicines and in medical research. PNI headquarters is located in Vancouver, Canada with scientist and sales support located globally and our instruments in over 20 countries.
PNI’s proprietary NanoAssembler Platform enables the rapid, reproducible, and scalable manufacture of next generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to cells and tissues in the body. PNI provides instruments, reagents and services to life sciences researchers, including pharmaceutical companies, and builds strategic collaborations to revolutionize healthcare through nanotechnology. This is illustrated by the one-hour video presenting breakthroughs in nanomedicines: https://youtu.be/hz27xoFddno.
Show all published submissions (1) Hide published submissions (1)
Submissions
List of Papers (1) Toggle list
D. Round Table on Parasitic Diseases
This round table is chaired by Dr. Conor Caffrey from the University of California at San Diego (USA).
Parasitic diseases continue to pose major public health problems, particularly in developing countries, worldwide. Moreover, the (re)appearance of these diseases in developed territories, such as schistosomiasis in Europe and Chagas disease in the southern United States, means that we must be increasingly vigilant in our preventive and response strategies as the global economy and climate change. However, the alarming ability of parasites to develop drug resistance combined with the small number of sometimes partially effective drugs available undermines our ability to manage and treat some diseases; a case in point being the emergence and establishment of drug resistance by the malaria parasite to artemisinin-based combination therapies (ACTs) over the last decade. Thus, there is a continuing, indeed, increasing, need to explore and develop new opportunities for chemotherapies. In this arena, the contribution of academia is vital. The current selection of papers submitted to this Round Table on Parasitic Diseases regarding leishmaniasis, trichomoniasis, Chagas disease, tuberculosis and Human African Trypanosomiasis attest to the continuing hard work and ingenuity of academic scientists to develop new ideas and approaches in the chemical battle against parasites. Importantly, in addition to synthetic chemical approaches described, we see the tapping of the vast chemical space of natural products as source of new drugs. It is hoped that the science presented at this Round Table will promote new exchanges and ideas among the chemical biology, parasitology and drug discovery communities, and ultimately contribute to the identification of novel therapeutic strategies.
Session Chair
Dr. Conor Caffrey
Show all published submissions (8) Hide published submissions (8)
Submissions
List of Papers (8) Toggle list